In California, a new bill (SB 17) was introduced seeking to advance the pricing transparency efforts of last year’s SB 1010 and promote fairer market practices for consumers. SB 17 was introduced on the first day of the 2017 Legislative Session. Last session, SB 1010 was delayed moving forward after amendments made it difficult to accomplish the ultimate goal of drug pricing transparency.
